Fludrokortizon

When ATH:
H02AA02

Pharmacological action.
Mineralocorticoid, glucocorticoid.

Application.

Primary and secondary adrenal insufficiency, congenital adrenal hyperplasia with marked loss of electrolytes; topically in ophthalmic practice: keratit, allergic diseases and eye injuries.

Contraindications.

Hypersensitivity, heart failure, hypertension, Hyper- and hypothyroidism, osteoporosis, of the liver and kidneys, systemic and local fungal infections, herpes, chronic infections, diabetes, peptic ulcer, diverticulitis, mental disorders, Pregnancy and breast-feeding; topical - fungal and bacterial eye damage.

Side effects.

Adrenal insufficiency, myasthenia, erosion of the gastrointestinal tract, increase the level of glucose, hyperkalemia, hypertension, headache, dizziness, euphoria, emotional lability, increased intraocular pressure (inside, locally), cataract formation (locally), menstrual irregularities, growth retardation in children, swelling.

Cooperation.

Increases efficiency (and toxicity) systemic gluco- and mineralocorticoid, It reduces - anabolic steroids (but increases their hepatotoxicity), oral antidiabetic drugs. It increases the likelihood of side effects in the appointment of cardiac glycosides, means, causing hypokalemia (Diuretic, amphotericin B). Against the backdrop of sodium-containing medicines increase the risk of edema and hypertension, acetylsalicylic acid and other NSAIDs - ulceration of the stomach lining. Psychotropic drugs and alcohol stimulates elimination.

Overdose.

Symptoms: arrhythmia, kaliopenia, hypertensive crisis, Eden, weight gain.

Dosing and Administration.

Inside - From 0,1 mg 3 twice a week to 0,2 mg 1 once a day. In chronic adrenal insufficiency, and adrenogenital syndrome - 0.1-0.2 mg / day together with hydrocortisone (10-30 Mg /), protractedly; eye ointment: lay behind the eyelid 1-3 times a day, no more 2 Sun.

Precautions.

A regular monitoring of blood pressure, Potassium and glucose levels in the blood. It should limit the intake of salt, prophylactically appoint drugs potassium, control the function of the adrenal cortex. The elongation rate is possible only at lower doses. After prolonged use of the abolition of the produce gradually (risk of adrenal insufficiency).

Cooperation

Active substanceDescription of interaction
AkarʙozaFMR: antagonizm. Against the background of the effect of fludrocortisone weakened; with a joint appointment is necessary to monitor the concentration of glucose in the blood.
Amphotericin BFMR: synergism. Against the background of fludrocortisone increases the likelihood of side effects (kaliopenia, dysfunctional disorders of the myocardium).
Acetylsalicylic acidFMR: synergism. Increases risk of side effects (ulceration and bleeding in the digestive tract).
BumetanidFMR: synergism. Increases (mutually) the likelihood of hypokalemia.
WarfarinFMR: antagonizm. Against the background of the effect of fludrocortisone weakened.
GidroxlorotiazidFMR: synergism. Increases (mutually) the likelihood of hypokalemia.
GlimepirideFMR: antagonizm. Against the background of weakening the effect of fludrocortisone; It requires the combined use of glucose monitoring.
GlipizideFMR: antagonizm. Against the background of the effect of fludrocortisone weakened; In sharing requires constant monitoring of blood glucose concentrations.
DigoxinFMR: synergism. Against the background of fludrocortisone increases the likelihood of side effects (hypokalemia and hypomagnesemia, decrease of potassium and magnesium in the myocardium increases its sensitivity).
Insulin aspartFMR: antagonizm. Against the background of the effect of fludrocortisone weakened; the combined use of increased insulin requirements.
Insulin dvuhfaznыy [human genetic engineering]FMR: antagonizm. Against the background of the effect of fludrocortisone weakened; the combined appointment of insulin dose should be increased (under the constant control of blood glucose levels).
Insulin soluble [pork monocomponent]FMR: antagonizm. Against the background of the effect of fludrocortisone weakened; joint application may need to increase the dose of insulin.
MetforminFMR: antagonizm. Against the background of reduced effect fludrocortisone; with a joint appointment required constant monitoring of blood glucose.
PioglitazoneFMR: antagonizm. Against the background of the effect of fludrocortisone weakened; Sharing requires constant monitoring of blood glucose levels.
Poliestradiola phosphateFKV. Increases kortikosteroidsvyazyvayuschego globulin, It reduces the amount of free (active) blood fractions.
ProtirelinFMR: antagonizm. Against the background of reduced effect fludrocortisone (stimulating the secretion of thyroid-stimulating hormone).
RepaglinideFMR: antagonizm. Against the background of the effect of fludrocortisone weakened; with a joint appointment is necessary to constantly monitor the concentration of glucose in the blood.
RifampicinFKV. Induces liver enzymes, accelerates biotransformation, increases clearance.
RosiglitazoneFMR: antagonizm. Against the background of the effect of fludrocortisone weakened; combined use necessitates constant monitoring of blood glucose concentration.
SomatropinFMR: antagonizm. Against the background of reduced effect fludrocortisone (stimulation of growth).
PhenytoinFKV. Accelerates biotransformation (induces liver enzymes), increases clearance.
PhenobarbitalFKV. Accelerates biotransformation (induces liver enzymes), increases clearance.
FurosemidFMR: synergism. Increases (mutually) the risk of hypokalemia.
EstradiolFKV. FMR: antagonizm. Reduces effect (kortikosteroidsvyazyvayuschego globulin increases and reduces the plasma concentration of the free - active - faction).
Ethacrynic acidFMR. Increases (mutually) the risk of hypokalemia.
EthanolFKV. It stimulates elimination.
EthinylestradiolFKV. Increases kortikosteroidsvyazyvayuschego globulin, It reduces the concentration of free active fraction of blood.

Back to top button